Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals
about
Vaccines against enteric infections for the developing worldAntigenic role of stress-induced catalase of Salmonella typhimurium in cell-mediated immunity.Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugatesEngineering filamentous phage carriers to improve focusing of antibody responses against peptides.Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.Development of Vi conjugate - a new generation of typhoid vaccine.Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhiSynthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linkerA Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in ChildrenAnti-pneumococcal antibody titre measurement: what useful information does it yield?Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Vaccination against typhoid fever: present statusConstruction of a recombinant oral vaccine against Salmonella typhi and Salmonella typhimuriumProtection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine.Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoidSynthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.Relation between structure and immunologic properties of the Vi capsular polysaccharide.Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight ViUnique lipid anchor attaches Vi antigen capsule to the surface of Salmonella enterica serovar Typhi.Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese childrenThe STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys.Anti-Infectious Human Vaccination in Historical Perspective.Specific and cross-reactive plasmablast response in humans after primary and secondary immunization with Vi capsular polysaccharide typhoid vaccine.A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.Oral enteric vaccines--clinical trials.Monoclonal antibodies against two discrete determinants on Vi capsular polysaccharide.Synthesis of the Heptasaccharide Repeating Unit of the Cell Wall O-Polysaccharide of Enterotoxigenic Escherichia coli O139.The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid.
P2860
Q28080866-C337D546-24B2-46CC-AD5B-7C768E79F493Q30979932-E2657D34-4B8D-47C8-8024-56B8E8B21D60Q33613531-01C436F4-1497-46D6-AE66-583C5062E8A7Q33695321-F9494C41-07AA-4162-BA86-656F208D6BD7Q34002415-89253586-7A4E-4FD8-AA34-0E2837EE9C05Q34179527-93520BB5-0C75-4876-89DE-AF894D7A1900Q34380025-9B322819-9ED6-4FCB-B47A-7437A3545EEDQ34541176-340D1449-5D23-4C0B-A154-87DE903EB334Q34548668-7EFC1E61-2AFE-4963-B5F7-8742293071FFQ35066191-50030A5B-61DC-4671-BD64-6E49F7386698Q35106317-472E1B00-C125-4754-9BED-99A6FB573CF6Q35425792-1E5AF672-D655-4F03-8259-CBE0E0412572Q35450564-2ED7FB02-F239-4AE7-9932-ADF317802172Q35548581-763D5BD7-4C3B-457B-BB22-F7DFB7BAEE89Q35792498-B020ECF6-9B17-447F-A061-533FD9CF5A08Q36026175-1CA492DE-DBD6-4201-BB2C-545F21BB46E3Q36128243-3DEA059A-3B9D-4C7E-9865-64D29A07785AQ36794750-30DBD3B4-101D-4D27-BD9F-39532EF1F52EQ36947654-51ADB9BE-309B-4C69-AEEA-29567BD3FE9CQ36970577-F142A7D1-3EB8-43AA-87D8-A39022002549Q36985836-E1AC903F-75DD-4982-9E39-2185998BDAFFQ36985988-895D2C72-BF50-4708-A186-23A3A041ECF8Q36989971-6B334EEB-D09E-44FF-9513-AD72A1A368E9Q36990350-7A5E2B51-3D6F-485F-8317-BB964A8FFE00Q36998805-93407BD7-7AB5-4F7A-9C49-F97C868B3BD0Q37007042-44A830EA-CA8E-4810-9FDF-B2C818812146Q37021713-38D348C9-91A0-4A3E-A7C6-089EB85D9C87Q37147461-B68D15B1-F88D-4B41-B75F-5840A1420EDCQ37582928-517908B8-8A31-42AF-A8CA-FD39A7B6B5C2Q38695279-24B580A0-8219-4BC4-A1A6-9D2596083E03Q40129444-03BC3BE4-07FE-4997-8246-FB9ABC4239ABQ40147988-1573A2A3-9286-4C43-AF88-A508148BCB10Q40291567-E96B34B3-484C-4D13-A0C2-9FE727BB7319Q40633156-AEA179E2-9669-49EE-ACD0-7BB3F283D106Q40744054-1DBB3581-51D7-4CE6-A4B7-6E251C0DE3F4Q40768357-18C58757-15CB-4FE8-B93D-789A1B304D76Q42173577-F3FA5AE9-357A-4AF2-9E3F-98945CE5AC55Q47245287-218E429C-3580-4BCB-815D-315235F197B4Q54216843-4A32BDFF-F9A9-446F-9116-D46D27940BD5
P2860
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@ast
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@en
type
label
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@ast
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@en
prefLabel
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@ast
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@en
P2093
P2860
P356
P1476
Vi capsular polysaccharide-pro ...... genicity in laboratory animals
@en
P2093
P2860
P304
P356
10.1084/JEM.166.5.1510
P407
P577
1987-11-01T00:00:00Z